(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 January 2020 (23.01.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/018413 A1

(51) International Patent Classification:
A61K 35/15 (2015.01) *C12N 5/10* (2006.01)
A61K 38/19 (2006.01) *C12N 15/09* (2006.01)
C07K 14/52 (2006.01) *C12N 15/63* (2006.01)
C07K 14/705 (2006.01) *C12N 15/85* (2006.01)
C12N 5/0784 (2010.01)

(21) International Application Number:
PCT/US2019/041786

(22) International Filing Date:
15 July 2019 (15.07.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/698,254 15 July 2018 (15.07.2018) US

(71) Applicant: **ENOCHIAN BIOPHARMA, INC.** [US/US]; 2080 Century Park East, Suite 906, Los Angeles, California 90067 (US).

(72) Inventor: **GUMRUKCU, Serhat**; 2080 Century Park East, Suite 906, Los Angeles, California 90067 (US).

(74) Agent: **SCOLNICK, Daniel M.**; Pepper Hamilton LLP, 400 Berwyn Park, 899 Cassatt Road, Berwyn, Pennsylvania 19312 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS AND COMPOSITIONS USING RECOMBINANT DENDRITIC CELLS FOR CANCER THERAPY




FIG.1A




FIG.1B




FIG.1C




FIG.1D

(57) Abstract: Disclosed herein are methods and compositions for treating cancer by eliciting an immune response by administering dendritic cells expressing heterologous proteins. In some embodiments, a dendritic cell comprises one or more heterologous nucleic acid molecules encoding for CD40L and CXCL13. In some embodiments, the dendritic cell further comprises a heterologous nucleic acid molecule encoding for CD93. In yet additional embodiments, the dendritic cells expressing heterologous proteins are activated.

[Continued on next page]

WO 2020/018413 A1

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*